TCG Crossover Management, LLC
- SEC CIK
- 0001839948
- Latest filing
- Aug 14, 2026
Holdings in Q2 2026
Holdings as of Jun 30, 2026, filed Aug 14, 2026. Long positions only; changes compare share counts with Q1 2026.
- Positions
- 54
- +5 vs. Q1 2026
- Portfolio value
- $4.16B
- +$665.1M (+19.0%) vs. Q1 2026
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ABVXAbivax S.A. | SPONSORED ADS | 6,007,834 | $800.6M | 19.2% | −473,251−7.3% | Reduced | History |
| TNGXTango Therapeutics, Inc. | COM | 9,081,201 | $283.9M | 6.8% | −1,449,870−13.8% | Reduced | History |
| CGONCG Oncology, Inc. | COM | 3,670,206 | $260.8M | 6.3% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 4,854,436 | $187.9M | 4.5% | −92,458−1.9% | Reduced | History |
| IMVTImmunovant, Inc. | COM | 4,457,988 | $171.8M | 4.1% | 00.0% | Unchanged | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 1,900,582 | $168.7M | 4.1% | 00.0% | Unchanged | History |
| DNTHDianthus Therapeutics, Inc. | COM | 1,676,624 | $163.4M | 3.9% | 00.0% | Unchanged | History |
| MIRMMirum Pharmaceuticals, Inc. | COM | 1,062,049 | $124.3M | 3.0% | 00.0% | Unchanged | History |
| ZLABZai Lab Ltd | ADR | 6,137,627 | $116.6M | 2.8% | +6,137,627 | New | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 6,243,812 | $112.1M | 2.7% | 00.0% | Unchanged | History |
| GLUEMonte Rosa Therapeutics, Inc. | COM | 4,622,151 | $111.9M | 2.7% | 00.0% | Unchanged | History |
| BCRXBiocryst Pharmaceuticals Inc | COM | 11,020,968 | $110.2M | 2.6% | 00.0% | Unchanged | History |
| VORVor Biopharma Inc. | COM NEW | 5,673,078 | $104.4M | 2.5% | 00.0% | Unchanged | History |
| TYRATyra Biosciences, Inc. | COM | 3,248,980 | $103.8M | 2.5% | 00.0% | Unchanged | History |
| DYNDyne Therapeutics, Inc. | COM | 4,615,144 | $102.5M | 2.5% | 00.0% | Unchanged | History |
| IRONDisc Medicine, Inc. | COM | 1,341,862 | $98.1M | 2.4% | 00.0% | Unchanged | History |
| RLAYRelay Therapeutics, Inc. | COM | 4,273,356 | $80.0M | 1.9% | 00.0% | Unchanged | History |
| SVRASavara Inc | COM | 12,362,205 | $76.2M | 1.8% | 00.0% | Unchanged | History |
| AURAAura Biosciences, Inc. | COM | 9,533,333 | $67.7M | 1.6% | +9,533,333 | New | History |
| RVMDRevolution Medicines, Inc. | COM | 340,899 | $63.8M | 1.5% | −235,574−40.9% | Reduced | History |
| TRAXFirst Tracks Biotherapeutics, Inc. | ORD SHS | 2,895,304 | $58.3M | 1.4% | +2,895,304 | New | History |
| KODKodiak Sciences Inc. | COM | 1,445,538 | $56.3M | 1.4% | 00.0% | Unchanged | History |
| AVTXAvalo Therapeutics, Inc. | COM NEW | 3,017,120 | $55.8M | 1.3% | +2,278,737+308.6% | Added | History |
| LBRXLB Pharmaceuticals Inc | COM SHS | 1,447,310 | $47.0M | 1.1% | −392,179−21.3% | Reduced | History |
| IPSCCentury Therapeutics, Inc. | COM | 17,754,430 | $43.4M | 1.0% | 00.0% | Unchanged | History |
| TECXTectonic Therapeutic, Inc. | COM | 1,204,891 | $41.4M | 1.0% | 00.0% | Unchanged | History |
| XNCRXencor Inc | COM | 2,452,138 | $39.5M | 0.9% | 00.0% | Unchanged | History |
| SRZNSurrozen, Inc. | COM NEW | 1,473,101 | $38.2M | 0.9% | 00.0% | Unchanged | History |
| EDITEditas Medicine, Inc. | COM | 11,111,111 | $36.0M | 0.9% | +11,111,111 | New | History |
| MBXMBX Biosciences, Inc. | COM | 650,000 | $35.9M | 0.9% | 00.0% | Unchanged | History |
| PHVSPharvaris N.V. | COM | 1,008,229 | $34.9M | 0.8% | +1,008,229 | New | History |
| SLNSilence Therapeutics plc | ADS | 3,033,560 | $33.3M | 0.8% | 00.0% | Unchanged | History |
| IFRXInflaRx N.V. | COM | 14,500,000 | $32.5M | 0.8% | +14,500,000 | New | History |
| ALTAltimmune, Inc. | COM NEW | 10,000,000 | $30.4M | 0.7% | +10,000,000 | New | History |
| JANXJanux Therapeutics, Inc. | COM | 1,789,617 | $27.5M | 0.7% | 00.0% | Unchanged | History |
| CATXPerspective Therapeutics, Inc. | COM NEW | 7,915,567 | $27.0M | 0.6% | 00.0% | Unchanged | History |
| AGMBAgomAb Therapeutics NV | SPONSORED ADS | 2,053,233 | $26.7M | 0.6% | 00.0% | Unchanged | History |
| BHVNBiohaven Ltd. | COM | 1,779,952 | $26.5M | 0.6% | −2,851,365−61.6% | Reduced | History |
| AKTSAktis Oncology, Inc. | COM | 696,560 | $22.5M | 0.5% | +696,560 | New | History |
| ALECAlector, Inc. | COM | 10,000,000 | $20.1M | 0.5% | 00.0% | Unchanged | History |
| FBRXForte Biosciences, Inc. | COM NEW | 920,000 | $19.6M | 0.5% | +920,000 | New | History |
| MNPRMonopar Therapeutics | COM NEW | 203,327 | $18.8M | 0.5% | +71,224+53.9% | Added | History |
| OCULOcular Therapeutix, Inc | COM | 1,647,752 | $16.2M | 0.4% | 00.0% | Unchanged | History |
| ADCTADC Therapeutics SA | SHS | 11,390,175 | $12.2M | 0.3% | 00.0% | Unchanged | History |
| ALXOAlx Oncology Holdings Inc | COM | 5,655,487 | $11.7M | 0.3% | −7,356,362−56.5% | Reduced | History |
| TRDAEntrada Therapeutics, Inc. | COM | 1,060,230 | $7.80M | 0.2% | −1,227,270−53.7% | Reduced | History |
| CGEMCullinan Therapeutics, Inc. | COM | 406,786 | $7.41M | 0.2% | 00.0% | Unchanged | History |
| ARVNArvinas, Inc. | COM | 707,098 | $5.88M | 0.1% | −1,680,363−70.4% | Reduced | History |
| KRROKorro Bio, Inc. | COM | 416,301 | $5.49M | 0.1% | 00.0% | Unchanged | History |
| RACCResearch Alliance Corp III | ORD SHS CL A | 500,000 | $5.35M | 0.1% | +500,000 | New | History |
| LONALeonaBio, Inc. | COM | 464,398 | $4.27M | 0.1% | 00.0% | Unchanged | History |
| JATTJATT II Acquisition Corp. | ORD SHS | 200,000 | $2.27M | 0.1% | +200,000 | New | History |
| CNTXContext Therapeutics Inc. | COM | 2,682,696 | $1.49M | <0.1% | 00.0% | Unchanged | History |
| EIKNEikon Therapeutics, Inc. | COM | 37,902 | $494.6K | <0.1% | +37,902 | New | History |
Sold out since Q1 2026 (7)
Positions held at the end of Q1 2026 that are gone from this filing.
| Security | Class | Shares in Q1 2026 | Value in Q1 2026 | % of portfolio in Q1 2026 | History |
|---|---|---|---|---|---|
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 4,286,480 | $170.3M | 4.9% | History |
| FULCFulcrum Therapeutics, Inc. | COM | 5,250,000 | $40.3M | 1.2% | History |
| LQDALiquidia Corp | COM NEW | 403,048 | $15.2M | 0.4% | History |
| URGNUroGen Pharma Ltd. | COM | 405,365 | $7.29M | 0.2% | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 140,411 | $6.77M | 0.2% | History |
| UPBUpstream Bio, Inc. | COM | 181,063 | $1.63M | <0.1% | History |
| VTGNVistagen Therapeutics, Inc. | COM | 2,676,580 | $1.53M | <0.1% | History |